Universal screening at age 1–2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis

Familial hypercholesterolaemia (FH) is widely underdiagnosed. Cascade testing (CT) of relatives has been shown to be feasible, acceptable and cost-effective in the UK, but requires a supply of index cases. Feasibility of universal screening (US) at age 1–2 years was recently demonstrated. We examine...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Atherosclerosis 2018-08, Vol.275, p.434-443
Hauptverfasser: McKay, Ailsa J., Hogan, Helen, Humphries, Steve E., Marks, Dalya, Ray, Kausik K., Miners, Alec
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 443
container_issue
container_start_page 434
container_title Atherosclerosis
container_volume 275
creator McKay, Ailsa J.
Hogan, Helen
Humphries, Steve E.
Marks, Dalya
Ray, Kausik K.
Miners, Alec
description Familial hypercholesterolaemia (FH) is widely underdiagnosed. Cascade testing (CT) of relatives has been shown to be feasible, acceptable and cost-effective in the UK, but requires a supply of index cases. Feasibility of universal screening (US) at age 1–2 years was recently demonstrated. We examined whether this would be a cost-effective adjunct to CT in the UK, given the current and plausible future undiagnosed FH prevalence. Seven cholesterol and/or mutation-based US ± reverse cascade testing (RCT) alternatives were compared with no US in an incremental analysis with a healthcare perspective. A decision model was used to estimate costs and outcomes for cohorts exposed to the US component of each strategy. RCT case ascertainment was modelled using recent UK CT data, and probabilistic Markov models estimated lifetime costs and health outcomes for the cohorts screened under each alternative. 1000 Monte Carlo simulations were run for each model, and average outcomes reported. Further uncertainty was explored deterministically. Threshold analysis investigated the association between undiagnosed FH prevalence and cost-effectiveness. A strategy involving cholesterol screening followed by diagnostic genetic testing and RCT was the most cost-effective modelled (incremental cost-effectiveness ratio (ICER) versus no US £12,480/quality adjusted life year (QALY); probability of cost-effectiveness 96·8% at £20,000/QALY threshold). Cost-effectiveness was robust to both deterministic sensitivity analyses and threshold analyses that modelled ongoing case ascertainment at theoretical maximum levels. These findings support implementation of universal cholesterol screening followed by diagnostic genetic testing and RCT for FH, under a UK conventional willingness-to-pay threshold.
doi_str_mv 10.1016/j.atherosclerosis.2018.05.047
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2059040534</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0021915018302909</els_id><sourcerecordid>2059040534</sourcerecordid><originalsourceid>FETCH-LOGICAL-c510t-fabd8045c3c548866c8f1c7e792433a26eb19d1467a3f93cc58569ac1dffcdfe3</originalsourceid><addsrcrecordid>eNqNkb-O1DAQxi0E4paDV0BukGgS7DjOHySK0wkOxEk0bG3NTsa3XjnJYjsnpeMFqHhDngSv9qCgQrLswr9v5pv5GHslRSmFbN4cSkh7CnNEf7pdLCshu1LoUtTtI7aRXdsXsu7qx2wjRCWLXmpxwZ7FeBAiI7J7yi6qvldtpZoN-7Gd3D2FCJ5HDESTm-44JA53xOWv7z8rvhKEyCGficNwWCZMPM0cISIMxBPFdNLYOXALo_Mul9qvRwq4n33-zC490OiAu4ln63z7-S2_4jjHVCwp82nNpcGveZbn7IkFH-nFw3vJth_ef73-WNx-ufl0fXVboJYiFRZ2QydqjQp13XVNg52V2FLbV7VSUDW0k_0g66YFZXuFqDvd9IBysBYHS-qSvT7XPYb525JNmtFFJO9honmJphK6F7XQqs7ouzOKedsxkDXH4EYIq5HCnBIxB_NPIuaUiBHa5HVn_cuHVstupOGv-k8EGbg5A5QHvncUTERHE9LgAmEyw-z-s9Vva7SqYg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2059040534</pqid></control><display><type>article</type><title>Universal screening at age 1–2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis</title><source>Elsevier ScienceDirect Journals</source><creator>McKay, Ailsa J. ; Hogan, Helen ; Humphries, Steve E. ; Marks, Dalya ; Ray, Kausik K. ; Miners, Alec</creator><creatorcontrib>McKay, Ailsa J. ; Hogan, Helen ; Humphries, Steve E. ; Marks, Dalya ; Ray, Kausik K. ; Miners, Alec</creatorcontrib><description>Familial hypercholesterolaemia (FH) is widely underdiagnosed. Cascade testing (CT) of relatives has been shown to be feasible, acceptable and cost-effective in the UK, but requires a supply of index cases. Feasibility of universal screening (US) at age 1–2 years was recently demonstrated. We examined whether this would be a cost-effective adjunct to CT in the UK, given the current and plausible future undiagnosed FH prevalence. Seven cholesterol and/or mutation-based US ± reverse cascade testing (RCT) alternatives were compared with no US in an incremental analysis with a healthcare perspective. A decision model was used to estimate costs and outcomes for cohorts exposed to the US component of each strategy. RCT case ascertainment was modelled using recent UK CT data, and probabilistic Markov models estimated lifetime costs and health outcomes for the cohorts screened under each alternative. 1000 Monte Carlo simulations were run for each model, and average outcomes reported. Further uncertainty was explored deterministically. Threshold analysis investigated the association between undiagnosed FH prevalence and cost-effectiveness. A strategy involving cholesterol screening followed by diagnostic genetic testing and RCT was the most cost-effective modelled (incremental cost-effectiveness ratio (ICER) versus no US £12,480/quality adjusted life year (QALY); probability of cost-effectiveness 96·8% at £20,000/QALY threshold). Cost-effectiveness was robust to both deterministic sensitivity analyses and threshold analyses that modelled ongoing case ascertainment at theoretical maximum levels. These findings support implementation of universal cholesterol screening followed by diagnostic genetic testing and RCT for FH, under a UK conventional willingness-to-pay threshold.</description><identifier>ISSN: 0021-9150</identifier><identifier>EISSN: 1879-1484</identifier><identifier>DOI: 10.1016/j.atherosclerosis.2018.05.047</identifier><identifier>PMID: 29937236</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Cost-effectiveness ; Hyperlipoproteinaemia type II ; Systematic population screening</subject><ispartof>Atherosclerosis, 2018-08, Vol.275, p.434-443</ispartof><rights>2018 Elsevier B.V.</rights><rights>Copyright © 2018 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c510t-fabd8045c3c548866c8f1c7e792433a26eb19d1467a3f93cc58569ac1dffcdfe3</citedby><cites>FETCH-LOGICAL-c510t-fabd8045c3c548866c8f1c7e792433a26eb19d1467a3f93cc58569ac1dffcdfe3</cites><orcidid>0000-0002-8221-6547</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.atherosclerosis.2018.05.047$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29937236$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McKay, Ailsa J.</creatorcontrib><creatorcontrib>Hogan, Helen</creatorcontrib><creatorcontrib>Humphries, Steve E.</creatorcontrib><creatorcontrib>Marks, Dalya</creatorcontrib><creatorcontrib>Ray, Kausik K.</creatorcontrib><creatorcontrib>Miners, Alec</creatorcontrib><title>Universal screening at age 1–2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis</title><title>Atherosclerosis</title><addtitle>Atherosclerosis</addtitle><description>Familial hypercholesterolaemia (FH) is widely underdiagnosed. Cascade testing (CT) of relatives has been shown to be feasible, acceptable and cost-effective in the UK, but requires a supply of index cases. Feasibility of universal screening (US) at age 1–2 years was recently demonstrated. We examined whether this would be a cost-effective adjunct to CT in the UK, given the current and plausible future undiagnosed FH prevalence. Seven cholesterol and/or mutation-based US ± reverse cascade testing (RCT) alternatives were compared with no US in an incremental analysis with a healthcare perspective. A decision model was used to estimate costs and outcomes for cohorts exposed to the US component of each strategy. RCT case ascertainment was modelled using recent UK CT data, and probabilistic Markov models estimated lifetime costs and health outcomes for the cohorts screened under each alternative. 1000 Monte Carlo simulations were run for each model, and average outcomes reported. Further uncertainty was explored deterministically. Threshold analysis investigated the association between undiagnosed FH prevalence and cost-effectiveness. A strategy involving cholesterol screening followed by diagnostic genetic testing and RCT was the most cost-effective modelled (incremental cost-effectiveness ratio (ICER) versus no US £12,480/quality adjusted life year (QALY); probability of cost-effectiveness 96·8% at £20,000/QALY threshold). Cost-effectiveness was robust to both deterministic sensitivity analyses and threshold analyses that modelled ongoing case ascertainment at theoretical maximum levels. These findings support implementation of universal cholesterol screening followed by diagnostic genetic testing and RCT for FH, under a UK conventional willingness-to-pay threshold.</description><subject>Cost-effectiveness</subject><subject>Hyperlipoproteinaemia type II</subject><subject>Systematic population screening</subject><issn>0021-9150</issn><issn>1879-1484</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqNkb-O1DAQxi0E4paDV0BukGgS7DjOHySK0wkOxEk0bG3NTsa3XjnJYjsnpeMFqHhDngSv9qCgQrLswr9v5pv5GHslRSmFbN4cSkh7CnNEf7pdLCshu1LoUtTtI7aRXdsXsu7qx2wjRCWLXmpxwZ7FeBAiI7J7yi6qvldtpZoN-7Gd3D2FCJ5HDESTm-44JA53xOWv7z8rvhKEyCGficNwWCZMPM0cISIMxBPFdNLYOXALo_Mul9qvRwq4n33-zC490OiAu4ln63z7-S2_4jjHVCwp82nNpcGveZbn7IkFH-nFw3vJth_ef73-WNx-ufl0fXVboJYiFRZ2QydqjQp13XVNg52V2FLbV7VSUDW0k_0g66YFZXuFqDvd9IBysBYHS-qSvT7XPYb525JNmtFFJO9honmJphK6F7XQqs7ouzOKedsxkDXH4EYIq5HCnBIxB_NPIuaUiBHa5HVn_cuHVstupOGv-k8EGbg5A5QHvncUTERHE9LgAmEyw-z-s9Vva7SqYg</recordid><startdate>201808</startdate><enddate>201808</enddate><creator>McKay, Ailsa J.</creator><creator>Hogan, Helen</creator><creator>Humphries, Steve E.</creator><creator>Marks, Dalya</creator><creator>Ray, Kausik K.</creator><creator>Miners, Alec</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8221-6547</orcidid></search><sort><creationdate>201808</creationdate><title>Universal screening at age 1–2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis</title><author>McKay, Ailsa J. ; Hogan, Helen ; Humphries, Steve E. ; Marks, Dalya ; Ray, Kausik K. ; Miners, Alec</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c510t-fabd8045c3c548866c8f1c7e792433a26eb19d1467a3f93cc58569ac1dffcdfe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Cost-effectiveness</topic><topic>Hyperlipoproteinaemia type II</topic><topic>Systematic population screening</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McKay, Ailsa J.</creatorcontrib><creatorcontrib>Hogan, Helen</creatorcontrib><creatorcontrib>Humphries, Steve E.</creatorcontrib><creatorcontrib>Marks, Dalya</creatorcontrib><creatorcontrib>Ray, Kausik K.</creatorcontrib><creatorcontrib>Miners, Alec</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Atherosclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McKay, Ailsa J.</au><au>Hogan, Helen</au><au>Humphries, Steve E.</au><au>Marks, Dalya</au><au>Ray, Kausik K.</au><au>Miners, Alec</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Universal screening at age 1–2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis</atitle><jtitle>Atherosclerosis</jtitle><addtitle>Atherosclerosis</addtitle><date>2018-08</date><risdate>2018</risdate><volume>275</volume><spage>434</spage><epage>443</epage><pages>434-443</pages><issn>0021-9150</issn><eissn>1879-1484</eissn><abstract>Familial hypercholesterolaemia (FH) is widely underdiagnosed. Cascade testing (CT) of relatives has been shown to be feasible, acceptable and cost-effective in the UK, but requires a supply of index cases. Feasibility of universal screening (US) at age 1–2 years was recently demonstrated. We examined whether this would be a cost-effective adjunct to CT in the UK, given the current and plausible future undiagnosed FH prevalence. Seven cholesterol and/or mutation-based US ± reverse cascade testing (RCT) alternatives were compared with no US in an incremental analysis with a healthcare perspective. A decision model was used to estimate costs and outcomes for cohorts exposed to the US component of each strategy. RCT case ascertainment was modelled using recent UK CT data, and probabilistic Markov models estimated lifetime costs and health outcomes for the cohorts screened under each alternative. 1000 Monte Carlo simulations were run for each model, and average outcomes reported. Further uncertainty was explored deterministically. Threshold analysis investigated the association between undiagnosed FH prevalence and cost-effectiveness. A strategy involving cholesterol screening followed by diagnostic genetic testing and RCT was the most cost-effective modelled (incremental cost-effectiveness ratio (ICER) versus no US £12,480/quality adjusted life year (QALY); probability of cost-effectiveness 96·8% at £20,000/QALY threshold). Cost-effectiveness was robust to both deterministic sensitivity analyses and threshold analyses that modelled ongoing case ascertainment at theoretical maximum levels. These findings support implementation of universal cholesterol screening followed by diagnostic genetic testing and RCT for FH, under a UK conventional willingness-to-pay threshold.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>29937236</pmid><doi>10.1016/j.atherosclerosis.2018.05.047</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-8221-6547</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-9150
ispartof Atherosclerosis, 2018-08, Vol.275, p.434-443
issn 0021-9150
1879-1484
language eng
recordid cdi_proquest_miscellaneous_2059040534
source Elsevier ScienceDirect Journals
subjects Cost-effectiveness
Hyperlipoproteinaemia type II
Systematic population screening
title Universal screening at age 1–2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T05%3A02%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Universal%20screening%20at%20age%201%E2%80%932%20years%20as%20an%20adjunct%20to%20cascade%20testing%20for%20familial%20hypercholesterolaemia%20in%20the%20UK:%20A%20cost-utility%20analysis&rft.jtitle=Atherosclerosis&rft.au=McKay,%20Ailsa%20J.&rft.date=2018-08&rft.volume=275&rft.spage=434&rft.epage=443&rft.pages=434-443&rft.issn=0021-9150&rft.eissn=1879-1484&rft_id=info:doi/10.1016/j.atherosclerosis.2018.05.047&rft_dat=%3Cproquest_cross%3E2059040534%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2059040534&rft_id=info:pmid/29937236&rft_els_id=S0021915018302909&rfr_iscdi=true